Lenz & Staehelin advised Kartesia, an European provider of financing solutions for small and mid-sized companies, which has provided a flexible secured debt financing package to support Symbios Orthopédie in its growth strategy. Lenz &
Tags :sx2
Bär & Karrer acted as legal advisor to MediaMarktSaturn on its agreement with Migros, according to which MediaMarktSaturn will take over 20 melectronics stores. The stores as well as the existing employees and apprentices will
Advestra advised Barry Callebaut on the placement of CHF 730 million bonds in the Swiss market on 17 May 2024. In addition, Barry Callebaut issued Eurobonds in the amount of EUR 700 mil
Homburger advised Aktiengesellschaft für die Neue Zürcher Zeitung (NZZ) on the acquisition of a 25%-stake in APG SGA (APG|SGA) from the two anchor shareholders JCDecaux, advised by Bär & Karrer, and
MLL advised Plasmalex on the acquisition of the swiss company Coat-X. The incorporation of implantable multilayer COAT-X thin films into Plasmalex’s product range represents a significant expansion of Plasmalex’s portfolio and will enable
Bär & Karrer advised Lalique Group on Silvio Denz’s – its majority shareholder – public tender offer for its publicly held registered shares. On 30 May 2024, Silvio Denz and Lalique entered into a transaction agreement regarding
Bratschi advised the shareholders of Mental Capital, an asset manager based in Lucerne, on its acquisition by Colombo Wealth. The team M&A partner Etienne Gard (pictured left) and tax partner Michael Barrot (pictured
Kellerhals Carrard advised Aitonomi in its intensified strategic partnership by Jost, which granted a convertible loan in the single digit million range for the achievement of its growth targets. Kellerhals Carrard team M&A /
Walder Wyss, together with CastaldiPartners, advised Provost on its acquisition of Mino & Lorenzini. Walder Wyss’ team comprised corporate and M&A partner Luc Defferrard (pictured) and corporate / M&A associate Ken Savioz.
Walder Wyss advised the funds managed by Pharmakon Advisors, an investor in non-dilutive debt for the life sciences industry and investment manager of the BioPharma credit funds. Banking and finance counsel Tervel Stoyanov (pictured left)
